Company insiders hold 1.30% of Veracyte's stock, while institutional investors have increased their stakes significantly, with Point72 Asset Management acquiring a new position worth $12.3 million. Analysts have given Veracyte a "Moderate Buy" rating, with a consensus price target of $34.80, despite mixed ratings from various firms. Recently, the company reported a quarterly EPS of $0.07, exceeding estimates, and a revenue increase of 26.7% year-over-year.